scholarly journals Nitric Oxide–Dependent Endothelial Dysfunction and Reduced Arginine Bioavailability in Plasmodium vivax Malaria but No Greater Increase in Intravascular Hemolysis in Severe Disease

2016 ◽  
Vol 214 (10) ◽  
pp. 1557-1564 ◽  
Author(s):  
Bridget E. Barber ◽  
Timothy William ◽  
Matthew J. Grigg ◽  
Kim A. Piera ◽  
Youwei Chen ◽  
...  

Background Pathogenesis of severe Plasmodium vivax malaria is poorly understood. Endothelial dysfunction and reduced nitric oxide (NO) bioavailability characterize severe falciparum malaria, but have not been assessed in severe vivax malaria. Methods In patients with severe vivax malaria (n = 9), patients with nonsevere vivax malaria (n = 58), and healthy controls (n = 79), we measured NO-dependent endothelial function by using reactive hyperemia–peripheral arterial tonometry (RH-PAT) and assessed associations with arginine, asymmetric dimethylarginine (ADMA), and hemolysis. Results The L-arginine level and the L-arginine to ADMA ratio (a measure of L-arginine bioavailability) were reduced in patients with severe vivax malaria and those with nonsevere vivax malaria, compared with healthy controls (median L-arginine level, 65, 66, and 98 µmol/mL, respectively [P = .0001]; median L-arginine to ADMA ratio, 115, 125, and 187, respectively [P = .0001]). Endothelial function was impaired in proportion to disease severity (median RH-PAT index, 1.49, 1.73, and 1.97 in patients with severe vivax malaria, those with nonsevere vivax malaria, and healthy controls, respectively; P = .018) and was associated with the L-arginine to ADMA ratio. While the posttreatment fall in hemoglobin level was greater in severe vivax malaria as compared to nonsevere vivax malaria (2.5 vs 1 g/dL; P = .0001), markers of intravascular hemolysis were not higher in severe disease. Conclusions Endothelial function is impaired in nonsevere and severe vivax malaria, is associated with reduced L-arginine bioavailability, and may contribute to microvascular pathogenesis. Severe disease appears to be more associated with extravascular hemolysis than with intravascular hemolysis.

2018 ◽  
Vol 2 (2) ◽  
pp. 8-15
Author(s):  
Gita Dwi Prasasty ◽  
Thia Prameswarie ◽  
Muhaimin Ramdja ◽  
Dwi Handayani

Abstract Background: Malaria infections cause various symptoms ranging from asymptomatic infections to severe disease complications. Plasmodium vivax malaria has been recognized as a disease that attacks blood cells, causing various hematologic changes, especially anemia, leukopenia, leukocytosis, neutropenia, neutrophilia, and thrombocytopenia with different percentages. Plasmodium vivax, formerly known to cause mild malaria, was later proven to cause severe malaria, even cerebral malaria such as Plasmodium falciparum. This study aims to determine the hematologic profile in patients with Plasmodium vivax malaria. Method: This research use descriptive cross sectional design. This research was conducted in Puskesmas (PKM; Primary Health Care) Sukamaju and Puskesmas (PKM; Primary Health Care) Karang City in August until December 2017. Samples were taken by consecutive sampling. A total of 37 samples expressed  positive Plasmodium vivax, examined their hematologic profiles specifically hemoglobin, erythrocytes, leucocytes, platelets, lymphocytes, neutrophils, monocytes and hematocrit using automatic hematology cell counter. Results: Based on the results of this study, 56.76% of patients had anemia, 45.90% of patients had  leukopenia, 89.20% thrombocytopenia, 2.70% neutrophilia, 10.80% neutropenia, 2.70% lymphocytosis, 35.10% lymphopenia, and 13.50% pancytopenia. Conclusion: In patients with Plasmodium vivax malaria infection there may be a change in hematologic profiles, this change may be affected by the acute phase of infection and host immune system.   Keywords: Plasmodium vivax malaria, hematologic profiles


2020 ◽  
Vol 26 (30) ◽  
pp. 3633-3651 ◽  
Author(s):  
Javier Blanco-Rivero ◽  
Fabiano E. Xavier

Cardiovascular diseases (CVD) are considered a major health problem worldwide, being the main cause of mortality in developing and developed countries. Endothelial dysfunction, characterized by a decline in nitric oxide production and/or bioavailability, increased oxidative stress, decreased prostacyclin levels, and a reduction of endothelium-derived hyperpolarizing factor is considered an important prognostic indicator of various CVD. Changes in cyclic nucleotides production and/ or signalling, such as guanosine 3', 5'-monophosphate (cGMP) and adenosine 3', 5'-monophosphate (cAMP), also accompany many vascular disorders that course with altered endothelial function. Phosphodiesterases (PDE) are metallophosphohydrolases that catalyse cAMP and cGMP hydrolysis, thereby terminating the cyclic nucleotide-dependent signalling. The development of drugs that selectively block the activity of specific PDE families remains of great interest to the research, clinical and pharmaceutical industries. In the present review, we will discuss the effects of PDE inhibitors on CVD related to altered endothelial function, such as atherosclerosis, diabetes mellitus, arterial hypertension, stroke, aging and cirrhosis. Multiple evidences suggest that PDEs inhibition represents an attractive medical approach for the treatment of endothelial dysfunction-related diseases. Selective PDE inhibitors, especially PDE3 and PDE5 inhibitors are proposed to increase vascular NO levels by increasing antioxidant status or endothelial nitric oxide synthase expression and activation and to improve the morphological architecture of the endothelial surface. Thereby, selective PDE inhibitors can improve the endothelial function in various CVD, increasing the evidence that these drugs are potential treatment strategies for vascular dysfunction and reinforcing their potential role as an adjuvant in the pharmacotherapy of CVD.


2020 ◽  
Vol 14 (7) ◽  
pp. e0007656
Author(s):  
João Conrado Khouri Dos-Santos ◽  
João Luiz Silva-Filho ◽  
Carla C. Judice ◽  
Ana Carolina Andrade Vitor Kayano ◽  
Júlio Aliberti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document